In consistent with above findings, we also found that low GATA3 mRNA predicted poor DMFS for patients with or without lymph node metastasis and that high FOSL1 predicted a poor outcome for patients with no lymph node metastasis. Here, GATA3 is linked to metastatic malignant neoplasm in the lymph nodes.